Company · CIK 0001652130 · SIC 2835 — In Vitro & In Vivo Diagnostic Substances · Nasdaq
Intellia Therapeutics, Inc. · NTLA
Insider activity reported against this company. All insider holders · On EDGAR ↗
Reported at this company — common stock
| Trade | Reported (ET) | Insider | Shares | Avg price | Total | Owned after | Δ stake | Flags |
|---|---|---|---|---|---|---|---|---|
| Aug 20, 2026 SForm 4 → | Aug 24, 4:05 pm EDT | John M LeonardPresident and CEO, Director | 22,675 | $12.65 | $286,819 | 1,147,064 | −1.94% | 10b5-1 |
| Jul 22, 2026 SForm 4 → | Jul 24, 5:26 pm EDT | Edward J Dulac IIIEVP, Chief Financial Officer | 8,111 | $11.25 | $91,249 | 148,175 | −5.19% | |
| Jul 2, 2026 SForm 4 → | Jul 6, 5:01 pm EDT | Edward J Dulac IIIEVP, Chief Financial Officer | 4,677 | $18.00 | $84,186 | 156,286 | −2.91% | 10b5-1 |
| Jul 1, 2026 SForm 4 → | Jul 6, 5:02 pm EDT | Michael P DubeVP, Chief Accounting Officer | 2,641 | $16.78 | $44,316 | 66,886 | −3.80% |
Reported at this company — derivatives (options, RSUs, warrants)
No reported derivative activity in this period.